Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma.
复制标题
Atezolizumab联合贝伐单抗治疗不可切除肝细胞癌患者期间监测肌肉体积的临床意义。
作者：
阿替唑单抗联合贝伐单抗治疗期间骨骼肌质量指数的降低与不能切除的肝细胞癌患者的无进展生存率显著相关，而治疗前的肌肉量减少并不是一个重要的因素。这些发现表明，在免疫治疗期间监测骨骼肌体积可能有助于预测临床结果。背景：在肝细胞癌患者中，骨量减少与总存活率有关。然而，目前尚不清楚肌肉体积是否与免疫检查点抑制剂联合治疗的临床结果有关。我们调查了阿替唑单抗联合贝伐单抗治疗的患者肌肉体积变化与治疗结果之间的关系。方法：选择2020年10月至2022年2月间接受阿替唑单抗联合贝伐单抗一线治疗的32例肝细胞癌患者。根据腰椎L3节段的骨骼肌面积计算骨骼肌质量指数(SMI)。比较给药后6~14周的SMI和SMI。结果：32例患者中，18例SMI降低，14例无SMI降低。SMI无下降患者的无进展生存期(PFS)显著长于SMI下降患者(8.5月vs.5.8个月，p=0.011)。在有无SMI的患者中，与治疗相关的不良事件没有显著差异。基线水平的低出生体征与PFS之间没有显著相关性。结论：SMI降低与PFS显著相关。在阿替唑单抗和贝伐单抗治疗期间监测肌肉容量在临床实践中是有用的。
Decrease of skeletal muscle mass index during atezolizumab plus bevacizumab therapy was significantly associated with poor progression-free survival in patients with unresectable hepatocellular carcinoma, while pretreatment sarcopenia was not a significant factor. These findings suggest that monitoring skeletal muscle volume during immunotherapy may be useful for predicting clinical outcomes. Background: Sarcopenia is associated with overall survival in patients with hepatocellular carcinoma (HCC). However, it is not known whether muscle volume is associated with clinical outcomes during combination therapy with immune checkpoint inhibitors. We investigated the relationship between changes in muscle volume and treatment outcomes in patients treated with atezolizumab plus bevacizumab. Methods: Thirty-two patients with HCC who received atezolizumab plus bevacizumab as the first-line treatment between October 2020 and February 2022 were included. Skeletal muscle mass index (SMI) was calculated from the skeletal muscle area at the L3 level of the lumbar vertebrae. We compared pretreatment SMI and SMI at 6–14 weeks after administration. Results: Of the 32 patients, 18 had a decreased SMI, while 14 did not. Progression-free survival (PFS) was significantly longer in patients without SMI decrease than in patients with SMI decrease (8.5 vs. 5.8 months, p = 0.011). There were no significant differences in treatment-related adverse events between the patients with and without SMI. Presarcopenia at baseline was not significantly associated with PFS. Conclusions: Decreased SMI was significantly associated with PFS. Monitoring muscle volume during atezolizumab plus bevacizumab therapy is useful in clinical practice.
登录
查看更多内容
影响因子：
5.9
作者：
Imai K;Takai K;Watanabe S;Hanai T;Suetsugu A;Shiraki M;Shimizu M
通讯作者：
Shimizu M
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
4
作者：
Tada, Toshifumi;Kumada, Takashi;Hiraoka, Atsushi;Hirooka, Masashi;Kariyama, Kazuya;Tani, Joji;Atsukawa, Masanori;Takaguchi, Koichi;Itobayashi, Ei;Fukunishi, Shinya;Tsuji, Kunihiko;Ishikawa, Toru;Tajiri, Kazuto;Ochi, Hironori;Yasuda, Satoshi;Toyoda, Hidenori;Ogawa, Chikara;Nishimura, Takashi;Hatanaka, Takeshi;Kakizaki, Satoru;Shimada, Noritomo;Kawata, Kazuhito;Tanaka, Takaaki;Ohama, Hideko;Nouso, Kazuhiro;Morishita, Asahiro;Tsutsui, Akemi;Nagano, Takuya;Itokawa, Norio;Okubo, Tomomi;Arai, Taeang;Imai, Michitaka;Naganuma, Atsushi;Koizumi, Yohei;Nakamura, Shinichiro;Joko, Kouji;Iijima, Hiroko;Hiasa, Yoichi
通讯作者：
Hiasa, Yoichi
影响因子：
4.1
作者：
Hiraoka A;Kumada T;Kariyama K;Tada T;Tani J;Fukunishi S;Atsukawa M;Hirooka M;Tsuji K;Ishikawa T;Takaguchi K;Itobayashi E;Tajiri K;Shimada N;Shibata H;Ochi H;Kawata K;Yasuda S;Toyoda H;Ohama H;Nouso K;Tsutsui A;Nagano T;Itokawa N;Hayama K;Arai T;Imai M;Koizumi Y;Nakamura S;Joko K;Michitaka K;Hiasa Y;Kudo M;Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
通讯作者：
Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi